Predicting Response to Anthracyclines
Developing targeted conventional therapies hampered by lack of understanding key events/pathways that lead to response/resistance
Lack of validated biomarkers
Co-ordinated molecular analysis of cell lines and clinical trial material has led to identification of histone assay
Assay has been validated in phase III clinical trial
Ongoing studies validating assay to level IA and IB
Histone assay is a potential tool that could be used by clinicians to determine if a patient could be spared anthracycline treatment.